Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 16, 2019. The document serves as a transaction notification reporting increases in shareholdings by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. These transactions were executed on April 12, 2019, on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transaction data:
- Transaction Type: Increase in interest in Ordinary Shares (ISIN: GB0009252882) and American Depositary Shares (ADSs) (ISIN: US37733W1053).
- Transaction Nature: Re-investment of dividends paid on April 11, 2019, under the Company's Deferred Annual Bonus Plan.
- Ordinary Share Price: GBP 15.6560 per share.
- ADS Price: USD 40.9400 per ADS.
- Total Volume (Ordinary Shares): 7,035,000 shares across 10 executives.
- Total Volume (ADSs): 1,064,000 ADSs across 4 executives.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. The only changes reported are the incremental increases in share ownership by specific executives resulting from the automatic re-investment of dividends.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a regulatory disclosure of routine executive compensation-related share transactions.
Important Facts for Investors to Verify
- Verify that the share price of GBP 15.6560 and USD 40.9400 aligns with market closing prices on April 12, 2019.
- Confirm the total number of shares acquired by PDMRs to assess insider accumulation trends relative to the broader market.
- Note that these transactions are non-discretionary dividend re-investments, not open-market purchases initiated by the executives.
- Check subsequent filings to ensure these transactions were properly reflected in the company's insider ownership tables.